Work

Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2591

Authors: Gerald Steven Falchook, Razelle Kurzrock, Hesham M. Amin, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku, Hongxia Zheng, Barbara Sarholz, Andreas Johne, David S. Hong

Institutions: HealthONE, Moores Cancer Center, The University of Texas MD Anderson Cancer Center, EMD Serono, Inc. (United States), Merck Healthcare KGaA, Darmstadt (Germany), Merck KGaA, Darmstadt (Germany)

Language: English

Topic: Cancer Mechanisms and Therapy

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921021975

Cites:

Cited by: 11

Related to: 10